BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
70.72
-3.21 (-4.34%)
Feb 19, 2026, 4:00 PM EST - Market closed
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 22 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $79.91, which forecasts a 12.99% increase in the stock price over the next year. The lowest target is $49 and the highest is $110.
Price Target: $79.91 (+12.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 9 | 9 | 9 | 8 | 8 |
| Buy | 9 | 9 | 10 | 12 | 13 | 14 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 18 | 19 | 21 | 21 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $100 | Strong Buy | Maintains | $90 → $100 | +41.40% | Feb 17, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $81 → $83 | Buy | Maintains | $81 → $83 | +17.36% | Feb 13, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $88 → $98 | Buy | Maintains | $88 → $98 | +38.57% | Feb 13, 2026 |
| Barclays | Barclays | Buy Initiates $80 | Buy | Initiates | $80 | +13.12% | Jan 28, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $84 → $88 | Buy | Maintains | $84 → $88 | +24.43% | Jan 20, 2026 |
Financial Forecast
Revenue This Year
507.45M
from 221.90M
Increased by 128.68%
Revenue Next Year
931.60M
from 507.45M
Increased by 83.58%
EPS This Year
-3.53
from -2.88
EPS Next Year
-1.86
from -3.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 548.1M | 1.3B | ||||
| Avg | 507.5M | 931.6M | ||||
| Low | 447.3M | 739.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 147.0% | 156.4% | ||||
| Avg | 128.7% | 83.6% | ||||
| Low | 101.6% | 45.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.19 | -0.71 | ||||
| Avg | -3.53 | -1.86 | ||||
| Low | -3.59 | -2.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.